Key TakeawaysNovo Nordisk's U.S.-listed shares rose Wednesday morning as third-quarter profits beat estimates and sales of Ozempic and Wegovy continued to grow.Sales rose 21% from the same time last year, but analysts had expected them to rise a bit higher.The Danish drugmaker also narrowed its full-year projections for revenue and operating profit. Novo Nordisk's (NVO) U.S.-listed shares rose Wednesday morning as it reported better third-quarter profits than expected, though sales of its drugs including po ...